Ipsen Press Releases | Latest News & Updates

– 10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…

– 05 June 2024

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary…

– 24 April 2024

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms &…

– 22 April 2024

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

– 02 April 2024

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

– 13 February 2024

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by…

– 08 February 2024

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 177 Press Releases

Show

Sort

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

– 10 June 2024

10 June 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination…

Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

– 07 June 2024

07 June 2024

Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

PARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics Inc, a clinical-stage biotech company, announced today the expansion of their ongoing oncology research partnership, to include TriSTAR, Marengo’s next-generation, precision T…

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

– 06 June 2024

06 June 2024

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

PARIS, FRANCE, 06 June 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August 19, 2024. He will serve on the Executive…

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

– 05 June 2024

05 June 2024

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

PARIS, FRANCE, 5 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced new late-breaking data at the European Association for the Study of the Liver (EASL) Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks…

Ipsen appoints Keira Driansky as EVP, President of North America

– 02 May 2024

02 May 2024

Ipsen appoints Keira Driansky as EVP, President of North America

PARIS, FRANCE, 2 May 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership…